Colitis ulcerosa: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• NLRP3 0
• NRF2 0
• STAT3 0
• JAK 2
• TNF 2
• IL-23 5
• TLR4 0
• MAPK 0
• PI3K 0
• PPAR 0
• AKT 0
• STING 0
• mTOR 0
• AMPK 0
• IL-6 0
• HIF-1 0
• TP53 0
• COX-2 0
• IL-17 0
• SIRT1 0
• CTNNB1 0
• GLP-1 0
• HMGB1 0
• HSP90 0
• IL-1 0
• CD40 0
• HDAC 1
• MMP-9 0
• GPX4 0
• JNK 0
• YAP 0
• EGFR 0
• CD19 3
• CTLA-4 0
• IL-4 0
• METTL3 0
• PARP 0
• VEGF 0
• BCMA 3
• ERK 0
• FOXP3 0
• MUC1 0
• PINK1 0
• ACE2 0
• G6PD 0
• IL-15 1
• KEAP1 0
• LRRK2 0
• MDM2 0
• PD-1 0
• PD-L1 0
• PKM2 0
• TIGIT 0
• BRD4 0
• CCR5 0
• CD30 0
• EZH2 0
• IL-13 0
• MYC 0
• PDE4 0

2100 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Microbiota-Ulcerative Colitis INterface: Phage-bacteria-immune interactions at the mucosal level. (MUCIN)

  Stichting Amsterdam Umc· Amsterdam, Hollandia· EU contribution 217 076 EUR· until 2028. ápr.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Characterising the molecular and cellular basis of enteric nervous system alterations in the inflamed gut (NeurogENSity)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 206 888 EUR· until 2027. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A Fibroblast-Targeting Advanced Lead Mitigating Inflammation and Fibrosis in IBD (FIBROLEAD)

  Inolysis Monoprosopi Idiotiki Kefalaiouchiki Etaireia· Melissia Athens, Görögország· EU contribution 150 000 EUR· until 2027. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Unravelling neuroimmune crosstalk to find novel treatment targets for inflammatory bowel disease (UNTANGLED)

  Stichting Amsterdam Umc· Amsterdam, Hollandia· EU contribution 432 468 EUR· until 2028. ápr.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Interplay of epithelial mechanics and neutrophil activation as a pathomechanism in refractory IBD and colorectal cancer patients (INTERCONNECTIONS)

  Universitatsklinikum Erlangen· Erlangen, Németország· EU contribution 173 847 EUR· until 2026. dec.

5 of 10 running projects, newest first. Listed amounts together: 19,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease

  NCT07250815· Takeda· Frissítve: 2026. okt. 15.

  “Sponsor decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Mirikizumab Real World Protocol

  NCT06696014· University of North Carolina, Chapel Hill· Frissítve: 2026. szept. 24.

  “Poor accrual”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Frissítve: 2026. szept. 21.

  “Administrative”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Prediction of Dietary Intervention Efficacy in Mild Ulcerative Colitis Patients Based on Fecal Microbiome Signatures

  NCT05579483· Wageningen University· Frissítve: 2026. aug. 20.

  “No funding”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Nicotinamide Riboside in Ulcerative Colitis

  NCT05561738· University of Pittsburgh· Frissítve: 2026. aug. 10.

  “This was a pilot study only. The primary goal of determining feasibility was achieved. Due to logistical issues and a desire to design a better trial, the study was terminated before reaching enrollment goals.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis

  NCT06681389· NIBEC Co., Ltd.· Frissítve: 2026. jún. 23.

  “Study was terminated at the end of Part A for strategic reasons (not due to lack of efficacy or safety issues”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study on Variation of Serum and Fecal Biomarkers After Treatment to Predict Mucosal Healing in Patients With Ulcerative Colitis

  NCT07653750· University Hospital, Clermont-Ferrand· Frissítve: 2026. jún. 17.

  “We were able to test our hypothesis using the current data”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

  NCT05785715· AbbVie· Frissítve: 2026. jún. 15.

  “Sponsor Decision\_Not Safety Related”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

  NCT05156125· Oppilan Pharma Ltd· Frissítve: 2026. ápr. 30.

  “The Induction and Long-Term Extension Periods were completed and analyzed as planned. The Sponsor decided to terminate clinical conduct in the Open-Label Extension Period. The decision to terminate the study was not due to safety concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Adjunctive Treatment With Vitamin D3 in Patients With Active IBD

  NCT04225819· Massachusetts General Hospital· Frissítve: 2026. ápr. 27.

  “Protocol is being modified.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

  NCT05668013· Teva Branded Pharmaceutical Products R&D LLC· Forrás

• A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

  NCT06636656· Boehringer Ingelheim· Forrás

• A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

  NCT07463183· Merck Sharp & Dohme LLC· Forrás

• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  NCT03816345· National Cancer Institute (NCI)· Forrás

• A study evaluating the effects of filgotinib in children and teenagers with ulcerative colitis

  2024-511458-32-00· Alfasigma S.p.A.· Forrás

• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

  2023-507853-13-00· Eli Lilly & Co.· Forrás

• Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

  NCT06651281· Merck Sharp & Dohme LLC· Forrás

• An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates

  NCT07923383· Sanofi· Forrás

• MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease

  NCT06788340· Odense University Hospital· Forrás

• An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

  NCT03950232· Pfizer· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 25
• Organoids 15
• Mendelian Randomization Analysis 48
• Gene Expression Profiling 76
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 5
• Proteomics 29
• Metabolomics 48
• Mass Spectrometry 5
• Flow Cytometry 8
• Immunohistochemistry 18
• Magnetic Resonance Imaging 10
• Machine Learning 43
• Deep Learning 11
• Cohort Studies 90
• Genome-Wide Association Study 56

• Central Nervous System Vasculitis Mimicking Glioma in a Patient With Ulcerative Colitis: A Case Report and Literature Review.

  J Dig Dis, 2026. okt.

• Imaging Updates in Inflammatory Bowel Disease.

  Magn Reson Imaging Clin N Am, 2026. júl.

• [A case of ulcerative colitis associated with chronic nonbacterial osteomyelitis].

  Zhonghua Er Ke Za Zhi, 2026. júl.

• Imaging endpoints in inflammatory bowel disease: current evidence and future directions for ultrasound and MRI.

  BMC Med, 2026. máj.

• Dolichocolon May Differentially Associate with Ulcerative Colitis Phenotype in Children.

  Dig Dis Sci, 2026. máj.

• Shared and distinct spontaneous brain activity pattern in crohn's disease and ulcerative colitis: evidence from cortical surface‑based analysis.

  BMC Gastroenterol, 2026. jan.

• Intestinal barrier healing is superior to transmural healing to prevent disease progression in clinical remittent patients with inflammatory bowel disease.

  J Crohns Colitis, 2026. jan.

• Causal effects of inflammatory bowel disease on brain structure: A Mendelian randomization study.

  Medicine (Baltimore), 2026. jan.

• Hepatobiliary and pancreatic findings on magnetic resonance enterography examinations in children with newly diagnosed inflammatory bowel disease.

  Pediatr Radiol, 2025. nov.

• [A case of acute masticatory muscle myositis successfully treated with corticosteroids].

  Rinsho Shinkeigaku, 2025. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.